Novartis Consumer Health, Inc. is voluntarily recalling certain lots of Triaminic® Syrups and Theraflu Warming Relief® Syrups that were manufactured in the United States prior to December 31, 2011.

Alcon today announced the launch of ILEVRO™ Suspension, a new once-daily treatment option for pain and inflammation associated with cataract surgery. In two double masked, randomized clinical trials, ILEVRO™ Suspension demonstrated superior clinical efficacy compared to its vehicle.

The thyroid gland which is located at the front of the neck near the clavicles is responsible for the rate of all metabolic and chemical processes in our body, in every cell, tissue and organ.

Respiratory syncytial virus (RSV) is a very common virus that leads to mild, cold-like symptoms in adults and older healthy children. But it can be far more serious in infants and toddlers, especially those in certain high-risk groups.

Merck today announced the company is taking steps to suspend the availability of TREDAPTIVE™ (extended-release niacin/ laropiprant ) tablets worldwide. TREDAPTIVE is not approved for use in the United States.

GTx , Inc. today announced that the US Food and Drug Administration (FDA) has designated enobosarm ( GTx-024 ) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer as a Fast Track development program.

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced top-line results for four completed Phase III clinical trials for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT-2) inhibitor being studied for treatment of patients with type 2 diabetes (T2D).

EMD Serono , Inc., a subsidiary of Merck KGaA , Darmstadt , Germany, and Pfizer Inc. announced today that the US Food and Drug Administration (FDA) approved Rebif ® Rebidose ® (interferon beta-1a ), a single-use auto-injector for the self-administration of Rebif , a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS).

Biogen Idec  reported top-line results of EMPOWER, a Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis (ALS). The trial did not meet its primary endpoint, a joint rank analysis of function and survival, and no efficacy was seen in the individual components of function or survival.

Dr. Reddy’s Laboratories announced today that is has launched f inasteride tablets (1 mg), a bioequivalent generic version of Propecia ® ( finasteride ) tablets in the US market on January 02, 2013. Dr. Reddy’s ANDA for f inasteride 1 mg Tablets has been awarded a 180-day period of marketing exclusivity in the US on 2 Jan, 2013.